Future Big BiTEs (6.28.2024)
Dr. Jack Cush reviews the news, journal articles and regulatory announcements from the past week on RheumNow.com.
News
Factors Affecting Hydroxychloroquine Adherence
A study from the University of British Columbia has evaluated the trajectories of hydroxychloroquine (HCQ) use in patients with incident RA and SLE between1997 and 2021, and identified factors associated with high adherence.
JAK Inhibitors in Giant Cell Arteritis
Trials are underway evaluating the potential benefits of JAK inhibitors (JAKi) in giant cell arteritis (GCA) patients who are refractory to standards of care.
Difficult-to-Treat Psoriasis
This meta-analysis of psoriasis treatments shows that biologic therapies may be less effective in certain psoriasis (PSO) patients, particularly those who are older, smokers, with higher BMI an prior exposure to biologics.
Low Back Pain? Take a Walk!
A randomised controlled trial of adults with recurrent low back pain (LBP) has shown that a program of progressive walking and education intervention significantly reduced low back pain recurrence.
Protective Benefits of SGLT2 Inhibitors and Lupus Nephritis
A multicenter cohort study of systemic lupus erythematosus patients with type 2 diabetes has shown the use of sodium-glucose cotransporter-2 (SGLT2) inhibitors associated with a significantly reduced risk of lupus nephritis, dialysis, kidney transplant, heart failure, and all-cause mortality compared with no SGLT2i use.
No Risk of Interstitial Lung Disease with Methotrexate Use
JAMA reports a cohort study that investigated the association between methotrexate (MTX) use and Interstitial lung disease (ILD) in patients with dermatomyositis (DM).
New indications for JAK inhibitors
There are several new positive RCTs for JAK inhibitors. Here is a summary of trials and new indications for JAKi in GCA, pediatrics, GI, dermatology and more.
Is Rheumatoid Arthritis Preventable?
Many conventional synthetic, biological, biosimilar, and targeted synthetic disease-modifying anti-rheumatic drugs are currently commercially available for the effective treatment of rheumatoid arthritis. However, the "Holy Grail" remains the prevention of its development. During a clinical symposium at EULAR 2024 in Vienna, updates were presented on four prospective intervention trials conducted in patients experiencing joint pain without visible joint swelling.
EULAR 2024 Rheumatology Roundup (6.21.2024)
Drs. Artie Kavanaugh and Jack Cush discuss highlights from the EULAR 2024 meeting in Vienna
The path to new technologies in rheumatology must be beset with caution
As we have incorporated technology into our workflows, and consequently saved lives and suffering, we have balanced our excitement about progress with proof that incremental advances can truly deliver benefit. it is easy to let promise carry our caution away - and while most of the time such advances come in a vetted package, which we can consume without concern, conference abstracts come raw. This is the necessary ingredient to a platform which allows for bold ideas and innovation, but for that reason it is not such a curated space. At EULAR 2024, we saw the usual mix of bright, raw ideas on the poster floor emblematic of this paradigm.
Personalized Exercise may have Key Benefits in Axial Spondyloarthritis
In a very interesting study at #EULAR2024, researchers demonstrated that personalized, supervised exercise therapy significantly improves physical function and quality of life for individuals with axial spondyloarthritis (axSpA) and severe functional limitations. This finding marks a critical advancement in the treatment of axSpA, particularly for patients with sustained disease activity, severe ankylosis, or significant comorbidities, who have historically been under-represented in research.
Damage in Childhood Lupus
EurekAlert!
Childhood lupus (cSLE) is a rare multisystem disorder with significant associated morbidity, but evidence-based guidelines are sparse, and as such management is often based on clinical expertise.
RA: update for women of child bearing potential (and men!)
Fertility in the context of RMDs is a daily concern for a lot of rheumatologists and patients. EULAR this year proposed new fertility data, especially in Rheumatoid Arthritis, along with an update of the EULAR points to consider for use of antirheumatic drugs in reproduction, pregnancy and lactation.
